Nemolizumab, an IL-31 inhibitor, has shown good efficacy and safety in treating prurigo nodularis over 52 weeks. It has also been found effective in treating atopic dermatitis, with positive long-term maintenance data. Current treatments for prurigo nodularis are not effective or well-tolerated, making the promise of nemolizumab significant. The drug has shown sustained improvement in itch, inflammation, lesion resolution, sleep quality, and quality of life. No serious adverse events have been reported, with manageable side effects like asthma exacerbation or peripheral edema. Nemolizumab has been submitted for FDA and EMA approval for both conditions.
Source link
Nemolizumab Efficacy Persists at 52 Weeks
